Cencora, Inc. (COR) Revenue CAGR:5.95%(TTM)
Revenue CAGR uses precomputed financial statement history.
Over longer horizons, Cencora, Inc.'s Revenue CAGR averages 9.91% over 3 years and 10.86% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Revenue CAGR measures how Cencora, Inc.'s top-line revenue has grown over time. Consistent revenue growth is a key indicator of business expansion and market share gains.
COR Revenue CAGR Chart
Cencora, Inc. (COR)
COR Quarterly Revenue Growth (YoY)
Revenue growth vs the same quarter one year earlier, last 20 quarters.
COR Revenue CAGR History
| Year | Start Revenue | End Revenue | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $293.96B | $321.33B | +$27.37B | +9.31% | +9.31% |
| 2024 | $262.17B | $293.96B | +$31.79B | +12.12% | +12.12% |
| 2023 | $238.59B | $262.17B | +$23.59B | +9.89% | +9.89% |
| 2022 | $213.99B | $238.59B | +$24.60B | +11.50% | +11.50% |
| 2021 | $189.89B | $213.99B | +$24.09B | +12.69% | +12.69% |
| 2020 | $179.59B | $189.89B | +$10.30B | +5.74% | +5.74% |
| 2019 | $167.94B | $179.59B | +$11.65B | +6.94% | +6.94% |
| 2018 | $153.14B | $167.94B | +$14.80B | +9.66% | +9.66% |
| 2017 | $146.85B | $153.14B | +$6.29B | +4.29% | +4.29% |
| 2016 | $135.96B | $146.85B | +$10.89B | +8.01% | +8.01% |
| 2015 | $119.57B | $135.96B | +$16.39B | +13.71% | +13.71% |
| 2014 | $87.96B | $119.57B | +$31.61B | +35.94% | +35.94% |
| 2013 | $79.49B | $87.96B | +$8.47B | +10.65% | +10.65% |
| 2012 | $80.22B | $79.49B | $-727.96M | -0.91% | -0.91% |
| 2011 | $77.95B | $80.22B | +$2.26B | +2.90% | +2.90% |
| 2010 | $71.76B | $77.95B | +$6.19B | +8.63% | +8.63% |
| 2009 | $70.19B | $71.76B | +$1.57B | +2.24% | +2.24% |
| 2008 | $66.07B | $70.19B | +$4.12B | +6.23% | +6.23% |
| 2007 | $61.20B | $66.07B | +$4.87B | +7.96% | +7.96% |
| 2006 | $54.58B | $61.20B | +$6.63B | +12.14% | +12.14% |
| 2005 | $53.18B | $54.58B | +$1.40B | +2.63% | +2.63% |
| 2004 | $49.66B | $53.18B | +$3.52B | +7.09% | +7.09% |
| 2003 | $45.23B | $49.66B | +$4.42B | +9.78% | +9.78% |
| 2002 | $16.19B | $45.23B | +$29.04B | +179.38% | +179.38% |
| 2001 | $11.65B | $16.19B | +$4.55B | +39.04% | +39.04% |
| 2000 | $9.81B | $11.65B | +$1.84B | +18.74% | +18.74% |
| 1999 | $8.67B | $9.81B | +$1.14B | +13.13% | +13.13% |
| 1998 | $7.82B | $8.67B | +$852.90M | +10.91% | +10.91% |
| 1997 | $5.55B | $7.82B | +$2.26B | +40.78% | +40.78% |
Quarterly Revenue: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q2 2026 | $78.36B | -8.8% | +3.8% |
| Q1 2025 | $85.93B | +2.6% | +5.5% |
| Q4 2025 | $83.73B | +3.8% | +5.9% |
| Q3 2025 | $80.66B | +6.9% | +8.7% |
| Q2 2025 | $75.45B | -7.4% | +10.3% |
| Q1 2024 | $81.49B | +3.1% | +12.8% |
| Q4 2024 | $79.05B | +6.5% | +14.7% |
| Q3 2024 | $74.24B | +8.5% | +10.9% |
| Q2 2024 | $68.41B | -5.3% | +7.8% |
| Q1 2023 | $72.25B | +4.8% | +15.0% |
| Q4 2023 | $68.92B | +3.0% | +12.7% |
| Q3 2023 | $66.95B | +5.5% | +11.5% |
| Q2 2023 | $63.46B | +1.0% | +9.9% |
| Q1 2022 | $62.85B | +2.7% | +5.4% |
| Q4 2022 | $61.17B | +1.8% | +3.8% |
| Q3 2022 | $60.06B | +4.1% | +12.5% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Cencora, Inc.
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Robert Mauch